Search

Your search keyword '"Chapman, Paul B."' showing total 24 results
Start Over Author "Chapman, Paul B." Publisher wiley
24 results on '"Chapman, Paul B."'

2. Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma

Author

Rosner, Samuel, primary, Kwong, Erica, additional, Shoushtari, Alexander N., additional, Friedman, Claire F., additional, Betof, Allison S., additional, Brady, Mary Sue, additional, Coit, Daniel G., additional, Callahan, Margaret K., additional, Wolchok, Jedd D., additional, Chapman, Paul B., additional, Panageas, Katherine S., additional, and Postow, Michael A., additional

Published
2018
Full Text
View/download PDF

4. MicroRNA‐125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway

Author

Koetz‐Ploch, Lisa, primary, Hanniford, Douglas, additional, Dolgalev, Igor, additional, Sokolova, Elena, additional, Zhong, Judy, additional, Díaz‐Martínez, Marta, additional, Bernstein, Emily, additional, Darvishian, Farbod, additional, Flaherty, Keith T., additional, Chapman, Paul B., additional, Tawbi, Hussein, additional, and Hernando, Eva, additional

Published
2017
Full Text
View/download PDF

8. Clinical activity of ipilimumab for metastatic uveal melanoma

Author

Luke, Jason J., primary, Callahan, Margaret K., additional, Postow, Michael A., additional, Romano, Emanuela, additional, Ramaiya, Nikhil, additional, Bluth, Mark, additional, Giobbie‐Hurder, Anita, additional, Lawrence, Donald P., additional, Ibrahim, Nageatte, additional, Ott, Patrick A., additional, Flaherty, Keith T., additional, Sullivan, Ryan J., additional, Harding, James J., additional, D'Angelo, Sandra, additional, Dickson, Mark, additional, Schwartz, Gary K., additional, Chapman, Paul B., additional, Wolchok, Jedd D., additional, Hodi, F. Stephen, additional, and Carvajal, Richard D., additional

Published
2013
Full Text
View/download PDF

16. Temozolomide plus thalidomide in patients with brain metastases from melanoma

Author

Hwu, Wen-Jen, primary, Lis, Eric, additional, Menell, Jennifer H., additional, Panageas, Katherine S., additional, Lamb, Lynne A., additional, Merrell, Janene, additional, Williams, Linda J., additional, Krown, Susan E., additional, Chapman, Paul B., additional, Livingston, Philip O., additional, Wolchok, Jedd D., additional, and Houghton, Alan N., additional

Published
2005
Full Text
View/download PDF

17. Evaluation of CD8+ T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide

Author

Lewis, Jonathan J., primary, Janetzki, Sylvia, additional, Schaed, Susanne, additional, Panageas, Katherine S., additional, Wang, Siqun, additional, Williams, Linda, additional, Meyers, Michael, additional, Butterworth, Leah, additional, Livingston, Philip O., additional, Chapman, Paul B., additional, and Houghton, Alan N., additional

Published
2000
Full Text
View/download PDF

22. A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma

Author

Steffens, Thomas A., primary, Bajorin, Dean F., additional, Chapman, Paul B., additional, Lovett, David R., additional, Cody-Johnson, Beverly V., additional, Templeton, Mary Agnes, additional, Heelan, Robert T., additional, Wong, George Y., additional, Portlock, Carol S., additional, Oettgen, Herbert F., additional, and Houghton, Alan N., additional

Published
1991
Full Text
View/download PDF

23. Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients.

Author

Belum VR, Rosen AC, Jaimes N, Dranitsaris G, Pulitzer MP, Busam KJ, Marghoob AA, Carvajal RD, Chapman PB, and Lacouture ME

Subjects
Adult, Aged, Benzimidazoles adverse effects, Carbamates adverse effects, Female, Humans, Imidazoles adverse effects, Indoles adverse effects, Male, Middle Aged, Oximes adverse effects, Skin Diseases complications, Sulfonamides adverse effects, Vemurafenib, Neoplasms drug therapy, Protein Kinase Inhibitors adverse effects, Skin Diseases chemically induced, Skin Diseases pathology
Abstract

Background: The use of BRAF inhibitors may lead to the development of cutaneous toxicities such as rashes, photosensitivity, alopecia, palmoplantar erythrodysesthesia, and proliferative skin lesions, including keratoacanthomas (KAs) and cutaneous squamous cell carcinomas (cuSCCs). The latter are noteworthy for their potential to exhibit malignant features, and they may necessitate invasive treatment. Their prompt identification is of primary importance for directing supportive care efforts and maintaining dose intensity while minimizing the morbidity associated with supportive care interventions. Because such lesions are less familiar to oncologists, this study was designed to characterize their clinico-morphological features, which have not been hitherto described., Methods: The clinical and dermoscopic characteristics and risk factors of new-onset proliferative skin lesions (benign verrucous lesions and KAs/cuSCCs) developing after the initiation of treatment with vemurafenib, dabrafenib, and XL281 were analyzed; the histopathological diagnoses were ascertained., Results: The majority of the lesions were benign verrucous lesions (78%, n = 87), whereas KAs/cuSCCs represented 22% (n = 25). The median times to biopsy for the initial verrucous lesions and KAs/cuSCCs were 4.8 and 10.5 weeks, respectively. The clinico-morphological features significant for KAs/cuSCCs included a larger size (P < .001), a nodular appearance (P < .001), a central keratin plug (P < .001), a central ulceration or crust (P = .04), an adherent scale (P = .02), an erythematous halo (P = .03), and a scaly ring (collarette; P < .001) at the periphery., Conclusions: Our findings represent the first detailed description of the clinico-morphological characteristics that permit distinction between the benign and malignant skin lesions induced by BRAF inhibitors. They are valuable for the recognition of lesions that require intervention and/or a dermatology referral versus those that permit provisional monitoring., (© 2014 American Cancer Society.)

Published
2015
Full Text
View/download PDF

24. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.

Author

Hwu WJ, Panageas KS, Menell JH, Lamb LA, Aird S, Krown SE, Williams LJ, Chapman PB, Livingston PO, Wolchok JD, and Houghton AN

Subjects
Adult, Aged, Aged, 80 and over, Dacarbazine administration & dosage, Dacarbazine analogs & derivatives, Eye Neoplasms pathology, Female, Follow-Up Studies, Humans, Interferon alpha-2, Interferon-alpha administration & dosage, Male, Middle Aged, Mouth Neoplasms pathology, Polyethylene Glycols, Recombinant Proteins, Remission Induction, Skin Neoplasms pathology, Survival Rate, Temozolomide, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Eye Neoplasms drug therapy, Melanoma drug therapy, Melanoma secondary, Mouth Neoplasms drug therapy, Skin Neoplasms drug therapy
Abstract

Background: Temozolomide and interferon-alpha-2b (IFN-alpha-2b) are both active in melanoma. Therefore, the efficacy and safety of temozolomide in combination with pegylated IFN-alpha-2b in patients with metastatic melanoma without brain metastases was investigated., Methods: Patients with histologically confirmed, unresectable, American Joint Committee on Cancer Stage IV melanoma were enrolled in an open-label, Phase II study. The primary endpoints were tumor response and safety. Patients received temozolomide (75 mg/m2/dayx6 weeks with a 2-week break between cycles) plus concomitant subcutaneous pegylated IFN-alpha-2b (0.5 microg/kg/wk, continuously). Treatment was continued until unacceptable toxicity or disease progression occurred., Results: Thirty-five patients (median age, 55 years) with Stage IV melanoma and a median of 3 metastatic sites were enrolled and received a median of 1 cycle (i.e., 8 weeks) of therapy (range, 0-6 cycles). Eleven patients (31%) (95% confidence interval, 16% to 47%) had an objective tumor response, including 3 with clinical complete response durations of 6 months, 20 months, and 32+ months and 8 with partial responses. Three patients with a partial or mixed response were subsequently rendered free of clinically detectable disease with surgery. The median survival was 12 months with a median follow-up among survivors of 16 months. No patient developed brain metastases while receiving study treatment. Treatment was generally well tolerated. Hematologic toxicity consisted mainly of lymphopenia and leukopenia (National Cancer Institute Common Toxicity Criteria Grades 1-3); no Grade 4 hematologic toxicity was observed., Conclusions: The combination of temozolomide plus pegylated IFN-alpha-2b had antitumor activity and was well tolerated in patients with metastatic melanoma. Therefore, further study is warranted., (Copyright (c) 2006 American Cancer Society.)

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results